AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12090410 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-wave intensive design
Number of subjects: 0
Study 12090410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest as a covariate
Number of subjects: 0
Study 12090410 — intervention group
Group type: COMPARATOR
Intervention: Standard analysis of covariance on the posttest with the pretest as covariate
Number of subjects: 0
Study 9647367 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 196
Study 7734015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 354
Study 7734015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 2481772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NIC) 20 mg t.i.d.
Number of subjects: 12
Study 2481772 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 50 mg b.i.d.
Number of subjects: 12
Study 2481772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine plus Captopril (NIC + CAP)
Number of subjects: 12
Study 2481772 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study 236075 — intervention group
Group type: EXPERIMENTAL
Intervention: Light anaesthesia with ketamine/diazepam
Number of subjects: 4
Study 236075 — intervention group
Group type: COMPARATOR
Intervention: Light halothane anaesthesia
Number of subjects: 4
Study 31419298 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO grade III versus IV
Number of subjects: 118
Study 31419298 — intervention group
Group type: EXPERIMENTAL
Intervention: H3F3A K27M mutation
Number of subjects: 118
Study 31419298 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline location
Number of subjects: 118
Study 31419298 — intervention group
Group type: EXPERIMENTAL
Intervention: High Ki-67 index (≥20%)
Number of subjects: 118
Study 31419298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 index increase
Number of subjects: 118
Study 30773441 — intervention group
Group type: EXPERIMENTAL
Intervention: 155° prosthesis
Number of subjects: 100
Study 30773441 — intervention group
Group type: COMPARATOR
Intervention: 135° prosthesis
Number of subjects: 100
Study 28947724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rivaroxaban
Number of subjects: 0
Study 28947724 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 26086281 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anaesthesia in lateral position
Number of subjects: 216
Study 26086281 — intervention group
Group type: COMPARATOR
Intervention: Deep anaesthesia in supine position
Number of subjects: 216
Study 26086281 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake in lateral position
Number of subjects: 216
Study 26086281 — intervention group
Group type: COMPARATOR
Intervention: Awake in supine position
Number of subjects: 216
Study 23098686 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9164 100 μg
Number of subjects: 28
Study 23098686 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9164 400 μg
Number of subjects: 28
Study 23098686 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9164 1200 μg
Number of subjects: 28
Study 23098686 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 28
Study 23098686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21421502 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase and argatroban administered regionally via small saphenous vein catheter
Number of subjects: 56
Study 21421502 — intervention group
Group type: COMPARATOR
Intervention: Urokinase and argatroban administered via peripheral vein (control)
Number of subjects: 56
Study 20195007 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational prevention program (PEP)
Number of subjects: 267
Study 20195007 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrist-enhanced PEP
Number of subjects: 267
Study 20195007 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-enhanced PEP
Number of subjects: 267
Study 20195007 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 267
Study 16893433 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d. for 12 weeks
Number of subjects: 60
Study 16893433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15330957 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural morphine 0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline (TEP group, n = 16)
Number of subjects: 32
Study 15330957 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion at 0.02 mg x kg(‐1) h(‐1) (INF group, n = 16)
Number of subjects: 32
Study 15330957 — intervention group
Group type: COMPARATOR
Intervention: Both TEP and INF groups
Number of subjects: 32
Study 11252116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid D-dimer assay
Number of subjects: 470
Study 11252116 — intervention group
Group type: COMPARATOR
Intervention: Control (no rapid D-dimer assay)
Number of subjects: 470
Study 9009045 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (standard behavior therapy protocol including in vivo and imagery exposure)
Number of subjects: 10
Study 9009045 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance program (for 5 patients)
Number of subjects: 10
Study 9009045 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients not in maintenance program)
Number of subjects: 10
Study 8390952 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interferon alfa‐2b (6 million units)
Number of subjects: 0
Study 8390952 — intervention group
Group type: COMPARATOR
Intervention: Standard dose interferon alfa‐2b (3 million units)
Number of subjects: 0
Study 8390952 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of plasma hepatitis C virus‐RNA
Number of subjects: 0
Study 30934001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stability RT (Smith machine)
Number of subjects: 59
Study 30934001 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium stability RT (Free-weight)
Number of subjects: 59
Study 30934001 — intervention group
Group type: EXPERIMENTAL
Intervention: High stability RT (Wobble board)
Number of subjects: 59
Study 30934001 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 30934001 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups
Number of subjects: 59
Study 30934001 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization period
Number of subjects: 59
Study 29165697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lift-less intervention (reducing lifting and carrying)
Number of subjects: 7
Study 26100254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet-assisted knee arthroplasty
Number of subjects: 28
Study 26100254 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 28
Study 24685847 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg weekly for 12 weeks
Number of subjects: 29
Study 24685847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium carbonate) for 12 weeks
Number of subjects: 29
Study 22142891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) intake for 3 weeks
Number of subjects: 72
Study 22142891 — intervention group
Group type: COMPARATOR
Intervention: Placebo intake for 3 weeks
Number of subjects: 72
Study 20431021 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐AE group (hypoxic‐absolute exercise, 50% maximum work rate under 15% O(2))
Number of subjects: 60
Study 20431021 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐RE group (hypoxic‐relative exercise, 50% maximal heart rate reserve under 15% O(2))
Number of subjects: 60
Study 20431021 — intervention group
Group type: COMPARATOR
Intervention: N‐E group (normoxic exercise, 50% maximum work rate under 21% O(2))
Number of subjects: 60
Study 20431021 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic (15% O(2)) resting control
Number of subjects: 60
Study 20431021 — intervention group
Group type: COMPARATOR
Intervention: Normoxic (21% O(2)) resting control
Number of subjects: 60
Study 18155500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonics + EDTA
Number of subjects: 100
Study 18155500 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 100
Study 18155500 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 100
Study 18155500 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonics
Number of subjects: 100
Study 18155500 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 18155500 — intervention group
Group type: EXPERIMENTAL
Intervention: MTwo‐PF drill
Number of subjects: 100
Study 18155500 — intervention group
Group type: EXPERIMENTAL
Intervention: Largo drill
Number of subjects: 100
Study 16160709 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 0
Study 16160709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14987202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 49
Study 14987202 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 49
Study 15016224 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 35
Study 15016224 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 35
Study 8958191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1 mg/day)
Number of subjects: 19
Study 8958191 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 19
Study 1286486 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 600 mg/day
Number of subjects: 172
Study 1286486 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 172
Study 3927650 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg L-Deprenyl per day
Number of subjects: 19
Study 3927650 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Deprenyl
Number of subjects: 19
Study 29688628 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg + Febuxostat 40 mg
Number of subjects: 23
Study 29688628 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad 2.5 mg + Febuxostat 80 mg
Number of subjects: 23
Study 29688628 — intervention group
Group type: COMPARATOR
Intervention: Verinurad 10 mg
Number of subjects: 23
Study 29688628 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat 40 mg
Number of subjects: 23
Study 29688628 — intervention group
Group type: COMPARATOR
Intervention: Verinurad 2.5 mg
Number of subjects: 23
Study 29688628 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat 80 mg
Number of subjects: 23
Study 29688628 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad
Number of subjects: 23
Study 29688628 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 23
Study 29688628 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad and Febuxostat combination
Number of subjects: 23
Study 29314344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fluoride varnish treatment (three applications within 2 weeks and additional applications at 1 and 3 months)
Number of subjects: 80
Study 29314344 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (semi-annual fluoride varnish treatment)
Number of subjects: 80
Study 27152633 — intervention group
Group type: EXPERIMENTAL
Intervention: TORS training curriculum with ex vivo dissection models
Number of subjects: 0
Study 25052229 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strain probiotic (Bifidobacterium animalis subsp. lactis Bl-04)
Number of subjects: 0
Study 25052229 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-strain probiotic (Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07)
Number of subjects: 0
Study 25052229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22613001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 101
Study 22613001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 19551536 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline trial participants
Number of subjects: 412
Study 19551536 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (Non-Invasive Ventilation)
Number of subjects: 412
Study 19551536 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG (Percutaneous Endoscopic Gastrostomy)
Number of subjects: 412
Study 19551536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life decline
Number of subjects: 412
Study 17935245 — intervention group
Group type: EXPERIMENTAL
Intervention: DALI (Fresenius)
Number of subjects: 6
Study 17935245 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposorber D (Kaneka)
Number of subjects: 6
Study 15695478 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga (KY) protocol
Number of subjects: 0
Study 15695478 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Response and Mindfulness Meditation (RRMM) techniques
Number of subjects: 0
Study 11859046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography and abdominal radiography
Number of subjects: 114
Study 11859046 — intervention group
Group type: COMPARATOR
Intervention: Intravenous urography
Number of subjects: 114
Study 10102764 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg bid)
Number of subjects: 0
Study 10102764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7778430 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol for 12 weeks
Number of subjects: 223
Study 7778430 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 223
Study 2112022 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programme carried out by nurses (home visit, 45 minutes assessment)
Number of subjects: 296
Study 475542 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Care
Number of subjects: 155
Study 475542 — intervention group
Group type: COMPARATOR
Intervention: Hospital Care
Number of subjects: 155
Study 31918682 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral design methodology to improve respectful maternity care
Number of subjects: 0
Study 30671586 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralaterally controlled functional electrical stimulation (CCFES)
Number of subjects: 41
Study 30671586 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuromuscular electrical stimulation (NMES)
Number of subjects: 41
Study 27681481 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based intervention
Number of subjects: 36
Study 27681481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rote exercise intervention
Number of subjects: 36
Study 27681481 — intervention group
Group type: COMPARATOR
Intervention: Control group (different activities with affected hand)
Number of subjects: 36
Study 26010687 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (1.5g, 15mL) three times a day orally or by another enteral route for 28 days
Number of subjects: 305
Study 26010687 — intervention group
Group type: EXPERIMENTAL
Intervention: Talactoferrin (1.5g, 15mL)
Number of subjects: 305
Study 26010687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 23395772 — intervention group
Group type: EXPERIMENTAL
Intervention: MHADRO (intervention)
Number of subjects: 836
Study 23395772 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 836
Study 21330636 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol · kg⁻¹ · min⁻¹)
Number of subjects: 12
Study 21330636 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (4 pmol · kg⁻¹ · min⁻¹)
Number of subjects: 12
Study 21330636 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 plus GIP
Number of subjects: 12
Study 21330636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18637139 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM-based VAS decision tool
Number of subjects: 138
Study 18637139 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM-based TTO decision tool
Number of subjects: 138
Study 17459479 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of intravitreal triamcinolone (TA)
Number of subjects: 111
Study 17459479 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of intravitreal triamcinolone (TA) combined with sequential grid laser
Number of subjects: 111
Study 17459479 — intervention group
Group type: COMPARATOR
Intervention: Grid laser photocoagulation
Number of subjects: 111
Study 14717388 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers in addition to digoxin, diuretics, and ACE inhibitors
Number of subjects: 0
Study 14717388 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 11115031 — intervention group
Group type: EXPERIMENTAL
Intervention: Early home-based intervention with weekly home visits from a child health nurse for 6 weeks, then fortnightly visits to 3 months, with some receiving short-term dynamic therapy from a social worker.
Number of subjects: 181
Study 11115031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 181
Study 9190006 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenin, 800 mg/day
Number of subjects: 192
Study 9190006 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen, 3000 mg/day
Number of subjects: 192
Study 1541877 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin as an adjuvant to standard treatment
Number of subjects: 196
Study 1541877 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin enantiomers (R,S) analysis
Number of subjects: 196
Study 1541877 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin disposition
Number of subjects: 196
Study 3020703 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide with CAV (cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 528
Study 3020703 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cranial irradiation
Number of subjects: 528
Study 3020703 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 528
Study 3020703 — intervention group
Group type: COMPARATOR
Intervention: Sequential hemibody radiotherapy
Number of subjects: 528
Study 31322496 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMC) transfer; 0.4 ml of cultured PBMCs transferred into the uterus two days prior to embryo transfer
Number of subjects: 250
Study 31322496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PBMC transfer)
Number of subjects: 250
Study 31322496 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMC) transfer; limited analysis to patients with ≥3 RIFs
Number of subjects: 250
Study 31322496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PBMC transfer); limited analysis to patients with ≥3 RIFs
Number of subjects: 250
Study 31229622 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM intervention (tablet-delivered goal setting tool, health coaching visit, twelve telephone calls, provider counseling training)
Number of subjects: 19
Study 31229622 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM intervention
Number of subjects: 19
Study 31229622 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) (health education materials)
Number of subjects: 19
Study 31229622 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 19
Study 28464026 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Na-GST-1 (10, 30, or 100 μg) adjuvanted with Alhydrogel
Number of subjects: 142
Study 28464026 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Na-GST-1/Alhydrogel with GLA-AF
Number of subjects: 142
Study 28464026 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 142
Study 24998403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous peripheral nerve stimulation (HF-TPNS)
Number of subjects: 10
Study 24322191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh cheese enriched with Bifidobacterium lactis Bi‐07 (30 g/day for 30 days)
Number of subjects: 30
Study 24322191 — intervention group
Group type: COMPARATOR
Intervention: Regular fresh cheese (30 g/day for 30 days)
Number of subjects: 30
Study 21969017 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 179
Study 21969017 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 179
Study 19358495 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine acupuncture at Dazhui (GV 14), Jingbailao (Ex‐HN 15), and Jianzhongshu (SI 15)
Number of subjects: 106
Study 19358495 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at 1 cm lateral to Bailao (Ex‐HN 15) and Jianzhongshu (SI 15)
Number of subjects: 106
Study 19358495 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (acupuncture)
Number of subjects: 106
Study 19358495 — intervention group
Group type: EXPERIMENTAL
Intervention: Attack frequency and duration of neck pain
Number of subjects: 106
Study 16424141 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation prior to squat exercise
Number of subjects: 0
Study 15580123 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 81
Study 15580123 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 81
Study 11167879 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red cells without buffy coat (PC group)
Number of subjects: 697
Study 11167879 — intervention group
Group type: COMPARATOR
Intervention: Filtered, leucoreduced, red cells (LD group)
Number of subjects: 697
Study 11167879 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfused patients
Number of subjects: 697
Study 11167879 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 697
Study 10773903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 40000
Study 10773903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega-dose capsule distribution
Number of subjects: 40000
Study 10773903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40000